Quinine sulfate as a therapeutic option in a patient with slow channel congenital myasthenic syndrome

Neuromuscular Disorders

Volumn 23, Issue 7, 2013, Pages 571-574

  Peyer, Anne Kathrin ^a   Abicht, Angela ^b   Heinimann, Karl ^c   Sinnreich, Michael ^a   Fischer, Dirk ^a,c  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

^b LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^c UNIVERSITY CHILDREN S HOSPITAL   (Switzerland)

Author keywords

Congenital myasthenic syndrome; Nicotinic acetylcholine receptor; Quinine sulfate; Slow channel congenital myasthenic syndrome

Indexed keywords

CHOLINERGIC RECEPTOR; FLUOXETINE; NICOTINIC RECEPTOR ALPHA; PYRIDOSTIGMINE; QUININE SULFATE; UNCLASSIFIED DRUG;

ADULT; AMINO ACID SUBSTITUTION; ANORGASMIA; ARTICLE; CASE REPORT; CONGENITAL MYASTHENIC SYNDROME; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; MUSCLE ACTION POTENTIAL; MUSCLE FATIGUE; MUSCLE STRENGTH; MUSCLE WEAKNESS; NERVE STIMULATION; ONSET AGE; OPHTHALMOPLEGIA; PRIORITY JOURNAL; PTOSIS; SOMNOLENCE; SWEAT GLAND DISEASE; TINNITUS; TREATMENT RESPONSE; TREMOR;

ADULT; FEMALE; HUMANS; MUTATION; MYASTHENIC SYNDROMES, CONGENITAL; NEUROMUSCULAR JUNCTION; QUININE; RECEPTORS, CHOLINERGIC; TREATMENT OUTCOME;

EID: 84878980807     PISSN: 09608966     EISSN: 18732364     Source Type: Journal    
DOI: 10.1016/j.nmd.2013.04.001     Document Type: Article

References (10)

1. Engel A.G., Shen X.-M., Selcen D., Sine S.M. What have we learned from the congenital myasthenic syndromes. J Mol Neurosci 2010, 40(1-2):143-153.
2. Chaouch A., Beeson D., Hantaï D., Lochmüller H. 186th ENMC international workshop: congenital myasthenic syndromes 24-26 June 2011, Naarden, The Netherlands. Neuromuscul Disord 2012, 22(6):566-576.
3. Chaouch A., Müller J.S., Guergueltcheva V., et al. A retrospective clinical study of the treatment of slow-channel congenital myasthenic syndrome. J Neurol 2012, 259(3):474-481.
4. Engel A.G. The therapy of congenital myasthenic syndromes. Neurotherapeutics 2007, 4(2):252-257.
5. Engel A.G. Current status of the congenital myasthenic syndromes. Neuromuscul Disord 2012, 22(2):99-111.
6. Mihaylova V., Müller J.S., Vilchez J.J., et al. Clinical and molecular genetic findings in COLQ-mutant congenital myasthenic syndromes. Brain 2008, 131(3):747-759.
7. Outteryck O., Richard P., Lacour A., et al. Novel {small element of} subunit mutation of the muscle acetylcholine receptor causing a slow-channel congenital myasthenic syndrome. J Neurol Neurosurg Psychiatry 2009, 80(4):450-451.
8. Harper C.M., Engel A.G. Quinidine sulfate therapy for the slow-channel congenital myasthenic syndrome. Ann Neurol 1998, 43(4):480-484.
9. Harper C.M., Fukodome T., Engel A.G. Treatment of slow-channel congenital myasthenic syndrome with fluoxetine. Neurology 2003, 60(10):1710-1713.
10. Sieb J.P., Milone M., Engel A.G. Effects of the quinoline derivatives quinine, quinidine, and chloroquine on neuromuscular transmission. Brain Res 1996, 712(2):179-189.